Central London’s private healthcare market is entering a more nuanced phase of its post‑pandemic cycle. Growth has not disappeared, but the easy gains of the Covid rebound have passed, leaving operators to navigate a landscape shaped by maturing PMI demand, price‑led self‑pay, and geopolitically exposed international flows. Few observers...
Cheplapharm, a family-run pharmaceutical company headquartered in Germany, specialising in the development, marketing, and distribution of branded pharmaceutical products, is aligning its management board for the company’s next phase of growth. As part of the reorganisation, the current CFO, Dr Keyarasch Parssanedjad, will assume the newly created role of Chief Business & Strategy Officer (CBSO) on June 1. He will be replaced by Martin Krämer.
Krämer was most recently CFO and director of HR at the chemical company Röhm. Prior to that, he held various financial and operational roles within the chemical industry. During...